세계의 다발성 혈관염 치료를 통한 호산구성 육아종증 치료 시장 보고서(2025년)

Eosinophilic granulomatosis with polyangiitis (EGPA) treatment involves medical strategies used to manage this uncommon autoimmune disorder, which leads to inflammation of small blood vessels. The primary goal of treatment is to reduce inflammation, manage symptoms, and halt disease progression.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The major drug classes in the eosinophilic granulomatosis with polyangiitis treatment market include steroids, immunosuppressants, biologics, and immune globulins. Steroids are a group of organic compounds that encompass both hormones and synthetic medications known for their anti-inflammatory and immunosuppressive effects. These medications can be administered through various routes, including oral, intravenous, and intramuscular. The distribution channels comprise online pharmacies, hospital pharmacies, drug stores, and retail pharmacies, while the end users include hospitals, clinics, and home healthcare providers.

The eosinophilic granulomatosis with polyangiitis treatment market research report is one of a series of new reports from The Business Research Company that provides eosinophilic granulomatosis with polyangiitis treatment market statistics, including eosinophilic granulomatosis with polyangiitis treatment industry global market size, regional shares, competitors with an eosinophilic granulomatosis with polyangiitis treatment market share, detailed eosinophilic granulomatosis with polyangiitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the eosinophilic granulomatosis with polyangiitis treatment industry. This eosinophilic granulomatosis with polyangiitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The eosinophilic granulomatosis with polyangiitis treatment market size has grown strongly in recent years. It will grow from$1.28 billion in 2024 to $1.41 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth during the historic period can be attributed to the rising incidence of Churg-Strauss syndrome, increasing demand for effective treatment options, a surge in research and development activities, an aging population, and growing awareness among patients.

The eosinophilic granulomatosis with polyangiitis treatment market size is expected to see strong growth in the next few years. It will grow to$2.06 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to a heightened focus on biologics and targeted therapies, an increase in clinical trial activity, the rise of patient advocacy movements, growing emphasis on precision medicine and personalized treatment, and the rising incidence of asthma among the aging population. Key trends expected during this period include technological advancements, progress in therapeutic agents and biologics, personalized medicine strategies, collaborations between healthcare providers and pharmaceutical companies, and the development of improved diagnostic methods.

The growing prevalence of asthma among the elderly is expected to drive the expansion of the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market in the coming years. Asthma, a condition that causes difficulty in breathing due to inflammation and narrowing of the airways, is becoming more common in older adults. As lung function declines with age, the elasticity of the lungs decreases, and airway muscles weaken, making breathing more challenging. This increased susceptibility to respiratory conditions makes elderly individuals more vulnerable to asthma. Asthma often serves as an early indicator of eosinophilic granulomatosis with polyangiitis, which further raises the demand for its treatment. For instance, according to the Global Initiative for Asthma in 2024, asthma is a widespread chronic non-communicable disease affecting over 260 million people worldwide and contributing to more than 450,000 deaths annually. As a result, the growing incidence of asthma in older populations is fueling the growth of the EGPA treatment market.

The rising frequency of allergic reactions is also expected to contribute to the growth of the eosinophilic granulomatosis with polyangiitis treatment market. The increasing presence of allergens due to air pollution-such as smoke, dust, and chemicals-leads to heightened sensitivity in the immune system. As allergic reactions become more prevalent, many individuals develop immune system disorders, such as eosinophilic granulomatosis with polyangiitis, which require effective treatments to manage inflammation and related symptoms. For example, in July 2024, the Allergy and Immunology Centre in the UK reported nearly 26,000 hospital admissions due to allergies and anaphylaxis between 2022 and 2023. This rising prevalence of allergic reactions is consequently driving the growth of the EGPA treatment market.

Clinical trials are playing a key role in advancing treatment innovations in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market. These trials are essential for evaluating the safety and effectiveness of both new and existing therapies, securing regulatory approvals, and improving patient care. For example, in September 2024, AstraZeneca, a UK-based pharmaceutical and biotechnology company, announced positive results from its MANDARA Phase III trial. The trial demonstrated that Fasenra (benralizumab) is effective in inducing remission in EGPA patients. The results showed that benralizumab achieved remission rates similar to those of mepolizumab, while also reducing the need for oral glucocorticoids. This advancement marks a significant step towards more targeted, steroid-sparing treatment approaches for eosinophilic granulomatosis with polyangiitis.

Major players in the eosinophilic granulomatosis with polyangiitis treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Roche Holding AG, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Intas Pharmaceuticals, Mylan N.V., Astellas Pharma Inc., Biogen Inc., Fresenius Kabi, Amgen Inc., Sun Pharmaceutical Industries, Apotex Inc., Cipla Ltd., Dr. Reddy's Laboratories, Lupin Limited, Alkem Laboratories, and NS Pharma.

North America was the largest region in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in eosinophilic granulomatosis with polyangiitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the eosinophilic granulomatosis with polyangiitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The eosinophilic granulomatosis with polyangiitis treatment market consists of sales of azathioprine, corticosteroids, methotrexate, and monoclonal antibodies such as mepolizumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Eosinophilic Granulomatosis With Polyangiitis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on eosinophilic granulomatosis with polyangiitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for eosinophilic granulomatosis with polyangiitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The eosinophilic granulomatosis with polyangiitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Steroids; Immunosuppressant; Biologics; Immune Globulins
• 2) By Route Of Administration: Oral; Intravenous; Intramuscular
• 3) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Drug Stores; Retail Pharmacies
• 4) By End User: Hospitals; Clinics; Home Healthcare
• Subsegments:
• 1) By Steroids: Glucocorticoids; Mineralocorticoids
• 2) By Immunosuppressants: Calcineurin Inhibitors; Antimetabolites; Alkylating Agents
• 3) By Biologics: Interleukin Inhibitors; Monoclonal Antibodies; TNF-alpha Inhibitors
• 4) By Immune Globulins: Intravenous Immunoglobulin (IVIG); Subcutaneous Immunoglobulin (SCIG)
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Eosinophilic Granulomatosis With Polyangiitis Treatment Market Characteristics

3. Eosinophilic Granulomatosis With Polyangiitis Treatment Market Trends And Strategies

4. Eosinophilic Granulomatosis With Polyangiitis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Eosinophilic Granulomatosis With Polyangiitis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market Growth Rate Analysis
• 5.4. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Total Addressable Market (TAM)

6. Eosinophilic Granulomatosis With Polyangiitis Treatment Market Segmentation

• 6.1. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Steroids
• Immunosuppressant
• Biologics
• Immune Globulins
• 6.2. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Intramuscular
• 6.3. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Pharmacies
• Hospital Pharmacies
• Drug Stores
• Retail Pharmacies
• 6.4. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Healthcare
• 6.5. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Sub-Segmentation Of Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glucocorticoids
• Mineralocorticoids
• 6.6. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Sub-Segmentation Of Immunosuppressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcineurin Inhibitors
• Antimetabolites
• Alkylating Agents
• 6.7. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interleukin Inhibitors
• Monoclonal Antibodies
• TNF-alpha Inhibitors
• 6.8. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Sub-Segmentation Of Immune Globulins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Immunoglobulin (IVIG)
• Subcutaneous Immunoglobulin (SCIG)

7. Eosinophilic Granulomatosis With Polyangiitis Treatment Market Regional And Country Analysis

• 7.1. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 8.1. Asia-Pacific Eosinophilic Granulomatosis With Polyangiitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 9.1. China Eosinophilic Granulomatosis With Polyangiitis Treatment Market Overview
• 9.2. China Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 10.1. India Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 11.1. Japan Eosinophilic Granulomatosis With Polyangiitis Treatment Market Overview
• 11.2. Japan Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 12.1. Australia Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 13.1. Indonesia Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 14.1. South Korea Eosinophilic Granulomatosis With Polyangiitis Treatment Market Overview
• 14.2. South Korea Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 15.1. Western Europe Eosinophilic Granulomatosis With Polyangiitis Treatment Market Overview
• 15.2. Western Europe Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 16.1. UK Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 17.1. Germany Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 18.1. France Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 19.1. Italy Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 20.1. Spain Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 21.1. Eastern Europe Eosinophilic Granulomatosis With Polyangiitis Treatment Market Overview
• 21.2. Eastern Europe Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 22.1. Russia Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 23.1. North America Eosinophilic Granulomatosis With Polyangiitis Treatment Market Overview
• 23.2. North America Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 24.1. USA Eosinophilic Granulomatosis With Polyangiitis Treatment Market Overview
• 24.2. USA Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 25.1. Canada Eosinophilic Granulomatosis With Polyangiitis Treatment Market Overview
• 25.2. Canada Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 26.1. South America Eosinophilic Granulomatosis With Polyangiitis Treatment Market Overview
• 26.2. South America Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 27.1. Brazil Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 28.1. Middle East Eosinophilic Granulomatosis With Polyangiitis Treatment Market Overview
• 28.2. Middle East Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Eosinophilic Granulomatosis With Polyangiitis Treatment Market

• 29.1. Africa Eosinophilic Granulomatosis With Polyangiitis Treatment Market Overview
• 29.2. Africa Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Eosinophilic Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Eosinophilic Granulomatosis With Polyangiitis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Eosinophilic Granulomatosis With Polyangiitis Treatment Market Competitive Landscape
• 30.2. Eosinophilic Granulomatosis With Polyangiitis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Eosinophilic Granulomatosis With Polyangiitis Treatment Market Other Major And Innovative Companies

• 31.1. Bristol Myers Squibb
• 31.2. AstraZeneca plc
• 31.3. Novartis AG
• 31.4. GSK plc
• 31.5. Roche Holding AG
• 31.6. Takeda Pharmaceutical Company
• 31.7. Teva Pharmaceutical Industries
• 31.8. Intas Pharmaceuticals
• 31.9. Mylan N.V.
• 31.10. Astellas Pharma Inc.
• 31.11. Biogen Inc.
• 31.12. Fresenius Kabi
• 31.13. Amgen Inc.
• 31.14. Sun Pharmaceutical Industries
• 31.15. Apotex Inc.

32. Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Eosinophilic Granulomatosis With Polyangiitis Treatment Market

34. Recent Developments In The Eosinophilic Granulomatosis With Polyangiitis Treatment Market

35. Eosinophilic Granulomatosis With Polyangiitis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Eosinophilic Granulomatosis With Polyangiitis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Eosinophilic Granulomatosis With Polyangiitis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Eosinophilic Granulomatosis With Polyangiitis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34844_Eosinophilic_Granulomatosis_With_Polyangiitis_Treatment_GMR_2025